Zentalis Pharmaceuticals’ (ZNTL) “Buy” Rating Reiterated at Guggenheim

Guggenheim reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report released on Friday,Benzinga reports. The brokerage currently has a $6.00 price target on the stock.

Separately, Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.17.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $2.10 on Friday. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $3.95. The company’s 50 day moving average price is $2.57 and its two-hundred day moving average price is $1.95. The firm has a market capitalization of $148.95 million, a price-to-earnings ratio of -1.11 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.08). As a group, equities research analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Activity at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters acquired 6,459,973 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the purchase, the insider owned 13,509,973 shares in the company, valued at $16,211,967.60. This trade represents a 91.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 46,617 shares of company stock valued at $113,417. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. 5AM Venture Management LLC raised its position in shares of Zentalis Pharmaceuticals by 705.7% in the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after acquiring an additional 3,457,913 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the period. Vanguard Group Inc. boosted its position in shares of Zentalis Pharmaceuticals by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after purchasing an additional 19,768 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Zentalis Pharmaceuticals by 24.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock valued at $3,893,000 after purchasing an additional 558,390 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Zentalis Pharmaceuticals by 117.1% during the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after purchasing an additional 835,466 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.